Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027
Source
171 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027
Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year
- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026
Expanded Product Portfolio in Optical Connectivity with Ultra-High Power Sources and Modules to Address Significant and Growing Demand for AI Data…
Record quarterly Revenue of $416.7 million, up 46% year-over-year
Won major new tier-1 FTCO customer and 4 tier-1 customers for Jivaro Pro in Q3
~Reports Fourth Quarter Revenue of $520.1 Million~
Conference Call and Webcast Today at 8:30 a.m. ET
Total Revenue of $45.3 Million, A Year over Year Increase of 11%, or 15% when Excluding the Contingent Matter in Q3 2025
Reaffirms Full-Year 2026 Guidance
Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency1)